The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Patient groups urge Congress to reauthorize Prescription Drug User Fee Act, improve clinical trial diversity

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Eighty-seven organizations representing patients with chronic and acute health conditions sent a letter to Congress urging them to improve the diversity of enrollment in clinical trials as part of this year’s Prescription Drug User Fee Act reauthorization. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Rezatapopt monotherapy shows confirmed responses of eight solid tumor types in PYNNACLE phase II clinical trial

Rezatapopt monotherapy generated a 33% overall response rate in 97 patients with solid tumors spanning across eight different cancers (ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma) and a median duration of response of 6.2 months, according to PYNNACLE phase II clinical trial interim data. These were patients whose tumors were TP53 Y220C mutated and KRAS wild-type. 
Podcast

Jonathan Mahler on his front-page story in the NYT Magazine on Trump’s deliberate dismantling of America’s War on Cancer

Readers of The Cancer Letter and listeners of The Cancer Letter Podcast are familiar with the impact of President Donald Trump’s first nine months in office on the field of oncology. Now, the threats posed to oncology are being brought to the attention of a general audience—Jonathan Mahler, staff writer for The New York Times Magazine, wrote an in-depth article about how the Trump administration’s actions have brought chaos, uncertainty, and damage to the oncology research community.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account